Lanean...
Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
Since 2005, an abundance of targeted agents has been approved for the treatment of metastatic renal cell carcinoma (mRCC), without any specification as to what may be the most optimal first-line and second-line sequence. Hence, our objective was to critically examine the evidence supporting the use...
Gorde:
| Argitaratua izan da: | Int J Nephrol Renovasc Dis |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2014
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4219683/ https://ncbi.nlm.nih.gov/pubmed/25378943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJNRD.S48496 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|